<DOC>
	<DOCNO>NCT02299817</DOCNO>
	<brief_summary>The main objective study efficacy denosumab reduce wear-induced osteolysis around uncemented acetabular implant use total hip arthroplasty . Patients include study receive dose 60 mg denosumab placebo ( 1 ml solution ) total 6 dos start day one every 6 month last treatment 30 month . The primary endpoint change volume osteolytic lesion 3 year measure ( measure 3D-CT cm³ ) .</brief_summary>
	<brief_title>Denosumab Treating Periprosthetic Osteolysis .</brief_title>
	<detailed_description />
	<mesh_term>Osteolysis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Age 4085 year Short Portable Mental Status Questionnaire ( SPMSQ ) also name pfeiffers test ≥7 Male females The primary total hip arthroplasty perform 7 20 year inclusion . The primary total hip arthroplasty perform due osteoarthritis congenital dysplasia hip . Uncemented cup fixation Baseline osteolytic lesion least 4 cm³ 40 cm³ around uncemented acetabular component polyethylene liner . Participant willing able follow study protocol provide informed consent prior study specific procedure . For woman childbearing potential : Subject refuse use 1 highly effective method contraception ( contraceptive pill , intra uterine contraceptive device ) duration study 10 month last dose study medication . For male partner childbearing potential : Subject refuse use condom duration study 10 month last dose study medication . For male partner pregnant : Subject refuse use condom duration study 10 month last dose study medication . Pain operate hip ( presence hip pain combination osteolytic lesion indication revision surgery ) . VAS &gt; 3 Previous revision surgery hip i.e . exchange inplant primary surgery Inflammatory arthritis Previous participation clinical trial denosumab administration commercial denosumab ( Prolia™ Xgeva™ ) Currently enrol yet complete least 1 month since end investigational device drug trial ( ) , subject receive investigational agent ( ) . Treatment intravenous bisphosphonate , fluoride ( except dental treatment ) strontium ranelate within 5 year prior inclusion . Treatment oral bisphosphonate within 1 year prior inclusion . Treatment cortisol cytostatic drug within 6 month prior inclusion . Administration follow treatment 3 month prior screen : Anabolic steroid testosterone Glucocorticosteroids ( ≥ 5 mg prednisone equivalent per day 10 day total cumulative dose ≥ 50 mg ) Calcitonin Calcitriol vitamin D derivatives [ vitamin D contain supplement multivitamin allow ] Other bone active drug include anti convulsive ( except benzodiazepine ) heparin Chronic systemic ketoconazole , adrenocorticotrophic hormone , cinacalcet , aluminum , lithium , protease inhibitor , methotrexate , gonadotropinreleasing hormone agonist . Androgen deprivation therapy Hypocalcaemia . Bone metabolic disorder ( OI , PHPT , Paget ) History osteonecrosis jaw and/or recent tooth extraction dental surgery ; plan invasive dental procedure study Serum 25OH D &lt; 20 ng/ml Significant malabsorption include Celiac Disease , Short Bowel Syndrome , Crohn 's Disease , Previous Gastric Bypass . Active cancer and/or malignancy last 5 year ( except cervical carcinoma situ basal cell carcinoma ) History solid organ bone marrow transplant . Hypersensitivity component study drug . Intolerance calcium supplement . Pregnancy and/or currently lactate . Significantly impaired renal function determine derived glomerular filtration rate ( GFR ) use Cockcroft Gault formula 30 mL/min/1.73 m2 Elevated transaminases ≥ 2.0 x upper limit normal ( ULN ) ; Elevated total bilirubin ( TBL ) &gt; 1.5 x ULN . Any condition illness ( acute , chronic , history ) , opinion Investigator might interfere evaluation efficacy safety study may otherwise compromise safety subject .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>